Drugs Made In America Acquisition Corp.

Drugs Made In America Acquisition Corp. (Nasdaq: DMAAR) is a blank-check company focused on the domestic pharmaceutical and drug manufacturing sector. The company filed a Form 10-K with the SEC on April 15, 2026, documenting its status as a special purpose acquisition company actively pursuing a business combination target within the U.S. life sciences and pharmaceutical supply chain space. DMAAR's sector focus reflects sustained investor and policy interest in reshoring domestic drug production. The annual filing, bearing accession number 0001213900-26-044139, is accessible through the SEC's EDGAR system. Sign up on SpacDesk for full sponsor profiles, deal timelines, and analytics coverage of DMAAR and the broader SPAC market.